Published in Emerg Infect Dis on March 01, 2013
Prevalence and Drug Resistance Patterns of Mycobacterium tuberculosis among New Smear Positive Pulmonary Tuberculosis Patients in Eastern Ethiopia. Tuberc Res Treat (2014) 1.05
Variation and risk factors of drug resistant tuberculosis in sub-Saharan Africa: a systematic review and meta-analysis. BMC Public Health (2015) 0.86
The movement of multidrug-resistant tuberculosis across borders in East Africa needs a regional and global solution. PLoS Med (2015) 0.85
Primary and secondary anti-tuberculosis drug resistance in Hitossa District of Arsi Zone, Oromia Regional State, Central Ethiopia. BMC Public Health (2016) 0.79
Predictors of multidrug resistant tuberculosis among adult patients at Saint Peter Hospital Addis Ababa, Ethiopia. Pan Afr Med J (2016) 0.75
Molecular detection of multidrug-resistant tuberculosis among smear-positive pulmonary tuberculosis patients in Jigjiga town, Ethiopia. Infect Drug Resist (2017) 0.75
Early initiation of antiretroviral treatment: Challenges in the Middle East and North Africa. World J Virol (2015) 0.75
Mycobacterium tuberculosis in central Ethiopia: drug sensitivity patterns and association with genotype. New Microbes New Infect (2017) 0.75
Drug susceptibility profiles of pulmonary Mycobacterium tuberculosis isolates from patients in informal urban settlements in Nairobi, Kenya. BMC Infect Dis (2016) 0.75
WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. Eur Respir J (2011) 8.96
Rapid molecular screening for multidrug-resistant tuberculosis in a high-volume public health laboratory in South Africa. Am J Respir Crit Care Med (2008) 7.47
Epidemiology of antituberculosis drug resistance 2002-07: an updated analysis of the Global Project on Anti-Tuberculosis Drug Resistance Surveillance. Lancet (2009) 7.22
GenoType MTBDR assays for the diagnosis of multidrug-resistant tuberculosis: a meta-analysis. Eur Respir J (2008) 4.32
A systematic review of the cost and cost effectiveness of treatment for multidrug-resistant tuberculosis. Pharmacoeconomics (2012) 2.36
Multidrug-resistant and extensively drug-resistant tuberculosis: a threat to global control of tuberculosis. Lancet (2010) 10.21
Epidemiology of antituberculosis drug resistance 2002-07: an updated analysis of the Global Project on Anti-Tuberculosis Drug Resistance Surveillance. Lancet (2009) 7.22
Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9,153 patients. PLoS Med (2012) 4.69
Surveillance of anti-tuberculosis drug resistance in the world: an updated analysis, 2007-2010. Bull World Health Organ (2011) 4.19
A postgenomic method for predicting essential genes at subsaturation levels of mutagenesis: application to Mycobacterium tuberculosis. Proc Natl Acad Sci U S A (2003) 3.70
Rapid molecular TB diagnosis: evidence, policy making and global implementation of Xpert MTB/RIF. Eur Respir J (2012) 2.47
Alarming levels of drug-resistant tuberculosis in Belarus: results of a survey in Minsk. Eur Respir J (2011) 2.33
Challenges in estimating the total burden of drug-resistant tuberculosis. Am J Respir Crit Care Med (2008) 2.33
Cost and cost-effectiveness of PPM-DOTS for tuberculosis control: evidence from India. Bull World Health Organ (2006) 2.31
Drug-resistant tuberculosis: time for visionary political leadership. Lancet Infect Dis (2013) 2.16
Universal access to care for multidrug-resistant tuberculosis: an analysis of surveillance data. Lancet Infect Dis (2013) 1.96
Predictors of poor outcomes among patients treated for multidrug-resistant tuberculosis at DOTS-plus projects. Tuberculosis (Edinb) (2012) 1.87
Multidrug-resistant tuberculosis in central Asia. Emerg Infect Dis (2004) 1.77
Xpert MTB/RIF for diagnosis of tuberculosis and drug-resistant tuberculosis: a cost and affordability analysis. Eur Respir J (2012) 1.70
Global epidemiology of tuberculosis. Semin Respir Crit Care Med (2013) 1.66
Multidrug-resistant tuberculosis in Belarus: the size of the problem and associated risk factors. Bull World Health Organ (2012) 1.62
WHO strategy for collecting safety data in public health programmes: complementing spontaneous reporting systems. Drug Saf (2013) 1.53
Zoonoses and marginalised infectious diseases of poverty: where do we stand? Parasit Vectors (2011) 1.44
Modernizing surveillance of antituberculosis drug resistance: from special surveys to routine testing. Clin Infect Dis (2011) 1.41
Alignment of new tuberculosis drug regimens and drug susceptibility testing: a framework for action. Lancet Infect Dis (2013) 1.39
Management of extensively drug-resistant tuberculosis in Peru: cure is possible. PLoS One (2008) 1.34
A systematic review of the effectiveness of hospital- and ambulatory-based management of multidrug-resistant tuberculosis. Am J Trop Med Hyg (2013) 1.16
Ambulatory-based standardized therapy for multi-drug resistant tuberculosis: experience from Nepal, 2005-2006. PLoS One (2009) 1.16
Scaling up programmatic management of drug-resistant tuberculosis: a prioritized research agenda. PLoS Med (2008) 1.15
Prevalence of tuberculosis suspects and their healthcare-seeking behavior in urban and rural Jordan. Am J Trop Med Hyg (2008) 1.08
Quantifying the burden and trends of isoniazid resistant tuberculosis, 1994-2009. PLoS One (2011) 1.08
Assessing spatial heterogeneity of multidrug-resistant tuberculosis in a high-burden country. Eur Respir J (2012) 1.04
Multidrug-resistant tuberculosis in children: evidence from global surveillance. Eur Respir J (2012) 1.03
The quality of antimalarials available in Yemen. Malar J (2005) 1.02
Implementing the global plan to stop TB, 2011-2015--optimizing allocations and the Global Fund's contribution: a scenario projections study. PLoS One (2012) 1.01
Are survey-based estimates of the burden of drug resistant TB too low? Insight from a simulation study. PLoS One (2008) 0.96
Tobacco use in the European region. Eur J Cancer Prev (2008) 0.96
Changing trends in peripartum hysterectomy over the last 4 decades. Am J Obstet Gynecol (2009) 0.96
E-cadherin determines Caveolin-1 tumor suppression or metastasis enhancing function in melanoma cells. Pigment Cell Melanoma Res (2013) 0.95
Mycobacterium tuberculosis genotype and case notification rates, rural Vietnam, 2003-2006. Emerg Infect Dis (2009) 0.95
Multidrug resistance among new tuberculosis cases: detecting local variation through lot quality-assurance sampling. Epidemiology (2012) 0.93
Use of anti-retroviral therapy in tuberculosis patients on second-line anti-TB regimens: a systematic review. PLoS One (2012) 0.93
Epidemiology of antituberculosis drug resistance in Saudi Arabia: findings of the first national survey. Antimicrob Agents Chemother (2013) 0.93
Monitoring Therapy Compliance of Tuberculosis Patients by using Video-Enabled Electronic Devices. Emerg Infect Dis (2016) 0.92
Occult hepatitis B virus infection among Egyptian blood donors. World J Hepatol (2013) 0.92
A systematic review of reported cost for smear and culture tests during multidrug-resistant tuberculosis treatment. PLoS One (2013) 0.91
Limitations on human rights: are they justifiable to reduce the burden of TB in the era of MDR- and XDR-TB? Health Hum Rights (2008) 0.91
Implementation of a national anti-tuberculosis drug resistance survey in Tanzania. BMC Public Health (2008) 0.90
Safety and availability of clofazimine in the treatment of multidrug and extensively drug-resistant tuberculosis: analysis of published guidance and meta-analysis of cohort studies. BMJ Open (2014) 0.83
WHO guidance on electronic systems to manage data for tuberculosis care and control. J Am Med Inform Assoc (2012) 0.82
Influenza research in the Eastern Mediterranean Region: the current state and the way forward. Influenza Other Respir Viruses (2013) 0.81
Morbidity of schistosomiasis mansoni in rural Alexandria, Egypt. J Egypt Soc Parasitol (2003) 0.80
E-health systems for management of MDR-TB in resource-poor environments: a decade of experience and recommendations for future work. Stud Health Technol Inform (2013) 0.80
Tb drug resistance: is it really a threat to Africa? Ethiop Med J (2007) 0.80
Maternal mortality and the rising cesarean rate. Int J Gynaecol Obstet (2011) 0.79
Genetic determinants of essential hypertension. J Egypt Public Health Assoc (2002) 0.79
Assessment of dietary exposure to some persistent organic pollutants in the Republic of Karakalpakstan of Uzbekistan. Environ Health Perspect (2003) 0.79
Mathematical Modeling of Programmatic Requirements for Yaws Eradication. Emerg Infect Dis (2017) 0.79
World Stop TB Day 2005: tuberculosis care providers and monitoring of treatment outcome in Europe. Euro Surveill (2005) 0.77
Progress in achieving universal access to care for multidrug- resistant tuberculosis (MDR-TB). Indian J Tuberc (2014) 0.76
HIV seroprevalence among new TB patients in the civilian and prisoner populations of Donetsk Oblast, Ukraine. Scand J Infect Dis (2008) 0.76
Paediatric tuberculosis in Europe: lessons from Denmark and inclusive strategies to consider. Eur Respir J (2014) 0.75
Safe water for the Aral Sea Area: could it get any worse? Eur J Public Health (2003) 0.75
Synercid plus vancomycin for the treatment of severe methicillin-resistant Staphylococcus aureus and coagulase-negative staphylococci infections: evaluation of 5 cases. Scand J Infect Dis (2002) 0.75
Assessment of nephrotoxicity of high-cumulative dose of liposomal amphotericin B in a pediatric patient who underwent allogeneic bone marrow transplantation. Pediatr Transplant (2006) 0.75